Lv3
250 积分 2024-01-20 加入
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial
4个月前
已完结
Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors
4个月前
已完结
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
4个月前
已完结
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Hemophilia A and B based on the GRADE methodology
5个月前
已完结
A survey of physicians’ treatment switching practice in people on long-term prophylaxis for hemophilia in five European countries
6个月前
已完结
Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry
6个月前
已完结
The value of ultrasonography in detecting early arthropathic changes and contribution to the clinical approach in patients of hemophilia
6个月前
已完结
Clinical severity of disease, functional disability and health-related quality of life. Three-year follow-up study of 150 Finnish patients with coagulation disorders
6个月前
已完结
The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIII
6个月前
已完结
皖公网安备34019202002308
